GI CANCERS

FDA grants tentative approval to PNT2003, a Lutathera radioequivalent PRRT for SSTR+ GEP-NETs, paving way for wider access by 2026.

FDA confirms first-line BRAF V600E mCRC gains: encorafenib plus cetuximab with FOLFOX or FOLFIRI improves PFS and OS.

FDA fast-tracks PLT012, a CD36 metabolic checkpoint antibody for liver cancer, as phase 1 trial tests safety and early efficacy.

Phase 3 BREAKWATER finds encorafenib+cetuximab+FOLFIRI improves PFS and response in first-line BRAF V600E metastatic colorectal cancer.

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.

FDA grants orphan drug designation to HCB101 for gastric cancer; early trials suggest safer CD47 checkpoint blockade with promising tumor control in advanced settings.

Nivolumab–ipilimumab extends survival in unresectable HCC, but US cost-effectiveness falls short; dosing changes or price cuts may shift value.

FDA approves Optune Pax, a wearable tumor treating fields device, to pair with GnP chemo in locally advanced pancreatic cancer, extending survival and delaying pain.

FDA fast-tracks irpagratinib for FGF19+ advanced liver cancer, with early trials showing strong response rates and ongoing combo study momentum.

Final MOUNTAINEER data show tucatinib plus trastuzumab delivers durable responses and manageable safety in HER2+ RAS wild-type metastatic colorectal cancer.

Interim DURIPANC data suggest rintatolimod plus durvalumab may extend survival and boost immune activity in post‑FOLFIRINOX metastatic pancreatic cancer.

Phase 3 interim data show anbenitamab plus chemo boosts survival and response in previously treated HER2-positive gastric cancer with manageable toxicity.

Dr. Mukherjee explores the future of antibody-drug conjugates in GI cancers, emphasizing precision medicine and targeted therapies for optimal patient outcomes.

FDA fast-tracks pelareorep with bevacizumab and FOLFIRI for KRAS-mutant MSS metastatic colorectal cancer, after standout response and survival signals.

Clinicians explore the shift towards earlier use of antibody-drug conjugates in GI oncology, aiming to enhance patient outcomes and treatment efficacy.

FDA reviews new drug applications for rivoceranib and camrelizumab as first-line treatments for advanced liver cancer, promising improved survival rates.

Explore the vital role of antibody-drug conjugates in precision oncology for GI malignancies, focusing on managing payload-dependent toxicities effectively.

Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.

FDA reviews zanzalintinib and atezolizumab for metastatic colorectal cancer, offering hope for patients with limited treatment options.

Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing precision and patient outcomes.

Lirafugratinib shows promise as a second-line treatment for cholangiocarcinoma, achieving significant response rates and durable outcomes in clinical trials.

New trial data show onvansertib enhances treatment response and progression-free survival in RAS-mutated metastatic colorectal cancer, paving the way for future therapies.

Dr. Filippo Pietrantonio explores the manageable safety profile of amivantamab combined with chemotherapy for metastatic colorectal cancer patients.

A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating patients with advanced rectal cancer with high Immunoscores.

Dr. Filippo Pietrantonio explores how amivantamab may transform surgical options for patients with advanced colorectal cancer, enhancing treatment outcomes.